70.24
                                            
            Tarsus Pharmaceuticals Inc stock is traded at $70.24, with a volume of 130.09K.
            It is up +1.89% in the last 24 hours and up +18.22% over the past month.
            Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
        
        See More
    Previous Close:
              $68.96
            Open:
              $68.72
            24h Volume:
                130.09K
            Relative Volume:
              0.20
            Market Cap:
                $2.96B
            Revenue:
              $17.39M
            Net Income/Loss:
              $-135.89M
            P/E Ratio:
              -15.14
            EPS:
                -4.64
            Net Cash Flow:
                $-123.00M
            1W Performance:
              +6.36%
            1M Performance:
              +18.22%
            6M Performance:
                +35.35%
            1Y Performance:
              +57.92%
            Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
                  
                      Tarsus Pharmaceuticals Inc
                    
                Sector
                  Industry
                  Phone
                  
                      (949) 409-9820
                    
                Address
                  
                      15440 LAGUNA CANYON ROAD, IRVINE
                    
                Compare TARS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS | 
|---|---|---|---|---|---|---|
|   
                          
                                TARS
                            
                             Tarsus Pharmaceuticals Inc | 70.22 | 2.91B | 17.39M | -135.89M | -123.00M | -4.64 | 
|   
                          
                                VRTX
                            
                             Vertex Pharmaceuticals Inc | 422.79 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 | 
|   
                          
                                REGN
                            
                             Regeneron Pharmaceuticals Inc | 655.88 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 | 
|   
                          
                                ALNY
                            
                             Alnylam Pharmaceuticals Inc | 452.12 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 | 
|   
                          
                                ARGX
                            
                             Argen X Se Adr | 812.69 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 | 
|   
                          
                                INSM
                            
                             Insmed Inc | 189.06 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 | 
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change | 
|---|---|---|---|
| Jun-02-25 | Resumed | Oppenheimer | Outperform | 
| May-27-25 | Resumed | H.C. Wainwright | Buy | 
| Nov-20-23 | Initiated | Goldman | Neutral | 
| Jul-18-23 | Initiated | William Blair | Outperform | 
| May-18-23 | Initiated | Guggenheim | Buy | 
| Aug-01-22 | Initiated | Barclays | Overweight | 
| Dec-21-21 | Initiated | H.C. Wainwright | Buy | 
| Nov-23-21 | Initiated | Oppenheimer | Outperform | 
| Nov-10-20 | Initiated | BofA Securities | Buy | 
| Nov-10-20 | Initiated | Jefferies | Buy | 
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy | 
| Nov-10-20 | Initiated | Raymond James | Strong Buy | 
                    View All
                     
                  
                Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Tarsus Pharmaceuticals (TARS) to Release Earnings on Tuesday - MarketBeat
What to expect from Tarsus Pharmaceuticals Inc. in the next 30 days2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
How analysts rate Tarsus Pharmaceuticals Inc. stock todayTrade Signal Summary & Low Risk Entry Point Guides - newser.com
What’s the recovery path for long term holders of Tarsus Pharmaceuticals Inc.2025 Volume Leaders & Long-Term Growth Stock Strategies - newser.com
Can Tarsus Pharmaceuticals Inc. recover in the next quarterPortfolio Profit Report & Safe Capital Growth Tips - newser.com
Top chart patterns to watch in Tarsus Pharmaceuticals Inc.CEO Change & Low Risk High Win Rate Stock Picks - newser.com
Jennison Associates LLC Trims Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Applying sector rotation models to Tarsus Pharmaceuticals Inc.2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Will Tarsus Pharmaceuticals Inc. stock deliver shareholder value2025 Market Overview & Weekly High Return Opportunities - newser.com
Is Tarsus Pharmaceuticals Inc. stock poised for growth2025 Market Outlook & Daily Stock Trend Watchlist - newser.com
Forecasting Tarsus Pharmaceuticals Inc. price range with options dataIndex Update & Weekly High Momentum Picks - newser.com
Is Tarsus Pharmaceuticals Inc. stock a safe investment in uncertain marketsTrade Risk Summary & Step-by-Step Swing Trade Plans - newser.com
Is Tarsus Pharmaceuticals Inc. stock cheap at current valuation2025 Price Action Summary & Reliable Entry Point Trade Alerts - newser.com
Is Tarsus Pharmaceuticals Inc. showing signs of accumulation2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
Full technical analysis of Tarsus Pharmaceuticals Inc. stockWeekly Investment Report & Verified Momentum Watchlists - newser.com
Tarsus Pharmaceuticals, Inc. to Host Live Webcast for Q3 2025 Financial Results and Corporate Update - Quiver Quantitative
Tarsus (NASDAQ: TARS) sets Nov. 4 webcast to share third‑quarter results at 1:30 p.m. PT - Stock Titan
Can Tarsus Pharmaceuticals Inc. stock sustain market leadershipPortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Is Tarsus Pharmaceuticals Inc. stock attractive for long term wealth building2025 Dividend Review & Technical Entry and Exit Tips - Fundação Cultural do Pará
How Tarsus Pharmaceuticals Inc. stock performs in weak economy2025 Performance Recap & Daily Entry Point Trade Alerts - Fundação Cultural do Pará
Does Tarsus Pharmaceuticals Inc. qualify in momentum factor screening2025 Technical Patterns & Safe Capital Preservation Plans - newser.com
Will Tarsus Pharmaceuticals Inc. stock gain from strong economyJuly 2025 Volume & Low Risk Entry Point Tips - Fundação Cultural do Pará
Can Tarsus Pharmaceuticals Inc. stock resist market sell offsSell Signal & Smart Allocation Stock Tips - newser.com
Capricorn Fund Loads Up on Phreesia (PHR) With a 484,000 Share Purchase - The Motley Fool
Tarsus Pharmaceuticals Inc. stock trend outlook and recovery pathWeekly Trend Report & Capital Efficiency Focused Strategies - newser.com
AlphaQuest LLC Has $836,000 Stake in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
        Open in Yahoo
        |
        Open in Google
            |
            Open in Finviz
        |
        Open in MarketWatch
            |
            Open in EDGAR    
        |
        Open in Reuters
    
    
                Cap:
                 
                  | 
                Volume (24h):
                 
            
         
                     
                             Get the Stockscreener App
                    Get the Stockscreener App